Sodium enoxaparin; Dimolegin; Dimolegin placebo; Sodium enoxaparine placebo
Проводит Avexima Diol LLC
Страница компанииRandomized, Double-blind, Double-masked Prospective Multicenter Trial to Evaluate the Efficacy and Safety of the Oral Anticoagulant Dimolegin® Compared With Low Molecular Weight Heparin (Clexane®) as a Means of Preventing VTE in Patients Undergoing Elective Endoprosthetics of Large Joints
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07124819/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–80 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 215 чел. во всех странах исследования.
- Центров в реестре: 8 в 8 городах. Список — ниже на странице.
- Плановая дата окончания (01.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 30
Критерии включения
- Men and women between the ages of 18 and 80.
- Patients scheduled for unilateral elective total hip or knee arthroplasty.
- The patient's voluntary informed consent.
- Negative pregnancy test result (for female patients with preserved reproductive potential).
- Patients with reproductive potential should agree to use methods of contraception according to the protocol.
Критерии невключения
- Surgery for an acute fracture (<4 weeks).
- Revision or extraction arthroplasty.
- Septic arthritis.
- The only lower limb.
- Increased risk of thrombosis.
- Active bleeding or increased risk of bleeding.
- Current coagulopathy (patient's or his relative's) or congenital thrombophilia.
- Collection of at least one volume unit of donated blood (≥ 450 ml) or blood transfusion during the previous 12 weeks.
- Surgery or injury during the last 90 days.
- Diseases of the digestive system that may disrupt the absorption of the study drug.
- Significant cardiovascular diseases currently or within 6 months prior to screening.
- Active liver or biliary tract diseases.
- Creatinine clearance, calculated according to the Cockcroft-Gault formula, less than 30 ml/min.
- Positive test result for HIV, syphilis, hepatitis B and C markers.
- The development of trophic disorders of the lower extremities that are not amenable to drug treatment.
- Any condition in which, in the opinion of the researcher, surgical intervention or the use of anticoagulants is contraindicated.
- Body mass index is less than 18.5 or more than 40 kg/m2.
- Body weight for women is less than 45 kg, for men less than 57 kg and above 130 kg for both.
- Systolic blood pressure > 180 mmHg and/or diastolic blood pressure >110 mmHg.
- Hemoglobin < 105 g/l in women or < 115 g/l in men.
- Abnormal results aboratory parameters of the coagulation system (platelets, APTT, prothrombin time, INR) beyond the limits of normal values.
- An increase in ALT or ACT ≥ 2 times from the upper limit of normal (ULN) or total bilirubin ≥ 1.5 times from ULN.
- Hypersensitivity or contraindications to the administration of Dimolegin®, enoxaparin sodium, unfractionated heparin or warfarin.
- The need for constant use of parenteral or oral anticoagulants.
- The need for continuous use of antiplatelet drugs, which cannot be discontinued at least 4 days before the start of the investigational therapy.
- Systemic therapy with drugs with strong inducers and inhibitors of CYP3A4 and P-glycoprotein, which cannot be discontinued at least 7 days before the start of the investigational therapy.
- Pregnant or breast-feeding women.
- Participation in another clinical trial currently or within 90 days prior to screening.
- Affiliation to a research center, Sponsor, or contractual research organization.
- Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; non-compliance with the study therapy or procedures.
Источник: ClinicalTrials.gov, NCT07124819 · запись обновлена в реестре 16 января 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 7
- Composite endpoint i.e.: confirmed symptomatic DVT, asymptomatic DVT, non fatal PE, death of all causes — up to the follow-up visit (28±2 days after the end of therapy)
Цель исследования
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing major joint (hip or knee) replacement surgery. The study will assess the incidence of VTE, VTE-related mortality, and all-cause mortality during different follow-up periods in both treatment groups. Additionally, the study will evaluate the frequency of bleeding events and the incidence, number, and characteristics of all adverse events associated with Dimolegin® and Clexane® therapy.
Где проходит
8 центров в 8 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07124819 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.